Results 1 to 10 of about 2,233 (157)

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease. [PDF]

Clin Transl Allergy
ABSTRACT Background Aspirin‐exacerbated respiratory disease (AERD), also termed nonsteroidal anti‐inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase‐1 inhibitors, frequently resulting in severe, treatment‐refractory airway disease ...
Priessnitz JK, Hagopian A, Patev AJ, Han JK, Lam KK.   +4 more
europepmc   +2 more sources

Navigating the small airways with tezepelumab. [PDF]

ERJ Open Res
Lim JV, Kuo CR, Chan R.
europepmc   +2 more sources

Real-World Effectiveness of Tezepelumab in Severe Asthma: A 12-Month Canadian Cohort Study. [PDF]

J Asthma Allergy
Saint-Pierre MD, Agaybi S, Charron CB, Leduc JG.   +3 more
europepmc   +1 more source

Exploring the Potential Benefits of Biologic Therapies Beyond Respiratory Allergy. [PDF]

Immunotargets Ther
Sica R, Catamerò F, Foti Randazzese S, Galletta F, Licari A, Marseglia GL, Mori F, Poto R, Pulvirenti F, Ricci S, Giovannini M, Manti S.   +11 more
europepmc   +1 more source

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study. [PDF]

Am J Respir Crit Care Med
Lugogo NL, Akuthota P, Sumino K, Burnette AF, Mathur SK, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B.   +9 more
europepmc   +1 more source

Persistent presumed allergic fungal rhinosinusitis during tezepelumab therapy with improvement after revision surgery: a case report. [PDF]

Front Allergy
Alsultan BSH, Alshehri AG, Sarhan LA, Alsultan GSH, Shabi Y.   +4 more
europepmc   +1 more source

Improvement of Severe Volume Dependent Airway Closure With Tezepelumab: A Case Report. [PDF]

Clin Case Rep
Suter P, Greig R, Chan R, Lipworth BJ.
europepmc   +1 more source

Tezepelumab in Chronic Rhinosinusitis with Nasal Polyps: Pathophysiology, Clinical Evidence, and Therapeutic Perspectives. [PDF]

Medicina (Kaunas)
Aigozhina B, Tulebaeyv R, Azhenov T, Dzhandayev S, Papulova N, Zhankina R, Sagandykova K.   +6 more
europepmc   +1 more source

Comments on "Established and Emerging Biological Therapies for the Treatment of Comorbid Asthma and Chronic Obstructive Pulmonary Disease" [Letter]. [PDF]

J Inflamm Res
Ambrose CS, Emmanuel B, Lugogo NL.
europepmc   +1 more source

Targeting upstream alarmins (TSLP, IL-33, IL-25): a new frontier in treating type 2 chronic rhinosinusitis with nasal polyps. [PDF]

Front Immunol
Li S.
europepmc   +1 more source